Programmable probiotics cut liver-failure toxins up to tenfold, offering hope beyond current drugs.
Singapore scientists have reprogrammed “good” gut bacteria to block brain-damaging toxins in liver failure, pointing to a new generation of microbe-based therapies for hepatic encephalopathy and other metabolic diseases.
Engineering The Gut To Save The Brain
In an eight year study published on April 24 in the journal Cell, researchers from the National University of Singapore engineered beneficial gut bacteria strains that prevented liver failure toxins from reaching the brain and reduced their build up, lowering ammonia levels by up to ten times to those seen in healthy conditions and sharply improving brain related outcomes in experimental models.
Limitations Of Current Liver Failure Treatments
Hepatic encephalopathy, a neurological complication of liver cirrhosis caused by ammonia that escapes a failing liver and floods the brain, is the top reason for hospital readmission in such patients and recurs in about 40 per cent of them, yet existing treatments like the laxative lactulose and the antibiotic rifaximin only partially cut ammonia production and can disturb the natural microbiome, leaving patients vulnerable to repeated, costly hospitalisations.
A New Class Of Live Biotherapeutics
Led by Professor Matthew Chang, director of NUS SynCTI, the team redesigned gut bacteria into two complementary therapeutic strains that can be taken as a powder or capsule, one absorbing excess ammonia in the gut and converting it into protein building amino acids, the other breaking down L glutamine before it turns into ammonia, a dual action approach that both removes toxins and restores essential nutrients without broadly suppressing native microbes.
Stronger Cognitive Benefits And Brain Protection
Compared with standard antibiotics, the engineered bacterial cocktail produced greater reductions in anxiety and short term memory loss, while neuronal signalling patterns returned toward normal and markers of brain inflammation fell, suggesting that targeted correction of gut metabolism can translate into central nervous system benefits and may overcome the weakness of conventional drugs that tackle only a single root cause of hepatic encephalopathy.
Safety, Patents And Future Applications
Senior research fellow Dr Nikhil Aggarwal said safety studies of around one month showed the strains were well tolerated, caused no systemic toxicity and were cleared within 72 hours of the final dose, while Prof Chang noted that NUS SynCTI has filed a patent to support clinical translation and plans to test long term performance and adapt the programmable microbe platform to other diseases driven by metabolic imbalance.
The NUS work highlights how synthetic biology can turn everyday gut bacteria into precise therapies that protect the brain from liver failure, easing burdens on patients and health systems in Indonesia, Singapore and beyond. For Indonesians, such advances offer hope against complications of cirrhosis in resource strained settings; for Singaporeans, they underscore the value of sustained investment in biomedical science that can move from bench to bedside and reshape how chronic diseases are managed across the region.
Sources: Straits Times (2026) , Yahoo! News Singapore (2026)
Keywords: Hepatic Encephalopathy, Engineered Gut Bacteria, NUS SynCTI, Brain Protection, Ammonia Toxins
